Search





Search





Markets
/
Stocks
/
cntb
/

Connect Biopharma Holdings Ltd

CNTB

Add to Watchlist

2.240USD

+0.040+1.82%

Close 07-23 16:00（ET）Quotes delayed by 15 min

140.47MMarket Cap

LossP/E TTM

Connect Biopharma Holdings Ltd

2.240

+0.040+1.82%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+1.82%

5 Days

-4.07%

1 Month

+7.18%

6 Months

-11.81%

Year to Date

-20.57%

1 Year

-1.32%

Key Figures

2.150Open

2.240High

86.00Volume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

0.00%Turnover Ratio

2.200Prev. Close

2.140Low

109.00Turnover

LossP/E Static

3.30P/B

0.00%Div Yield TTM

-84.59%ROA

3.82052wk High

-0.00Volume Ratio

-15.63MNet Profit

62.71MShares

-1.1542EPS TTM

-0.22Beta

-102.94%ROE

0.73052wk Low

4.55%Amplitude

100.00%Gross Margin

140.47MMarket Cap

0.63Reward/Risk

5.99%Risk Rate

TradingKey Stock Score of Connect Biopharma Holdings Ltd

Currency: USD Updated: 2026-07-23

Key Insights

Connect Biopharma Holdings Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 127 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.12.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Connect Biopharma Holdings Ltd's Score

Industry at a Glance

Industry Ranking

127 / 386

Overall Ranking

201 / 4547

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Connect Biopharma Holdings Ltd Highlights

StrengthsRisks

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Growing

The company is in a growing phase, with the latest annual income totaling USD 64.00K.

Overvalued

The company’s latest PE is -1.91, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 29.94M shares, increasing 21.31% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 21.58K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.83.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

7.125

Target Price

+222.40%

Upside Space

Connect Biopharma Holdings Ltd News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 8 analysts

Buy

Current Rating

7.125

Target Price

+222.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

495

Total

Median

Average

Company name

Ratings

Analysts

Connect Biopharma Holdings Ltd

CNTB

Beigene Ltd

ONC

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

Insmed Inc

INSM

...

Indicators

Indicators

Sell(1)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.040

Neutral

RSI(14)

46.279

Neutral

STOCH(KDJ)(9,3,3)

12.678

Oversold

ATR(14)

0.222

High Vlolatility

CCI(14)

-95.624

Neutral

Williams %R

91.304

Oversold

TRIX(12,20)

0.181

Sell

StochRSI(14)

0.443

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.238

Buy

MA10

2.308

Sell

MA20

2.320

Sell

MA50

2.276

Sell

MA100

2.500

Sell

MA200

2.394

Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Connect Biopharma Holdings Ltd Info

Ticker SymbolCNTB

CompanyConnect Biopharma Holdings Ltd

CEOQuart (Barry D)

Websitehttps://www.connectbiopharm.com

Shareholders

Shareholders

Proportion

Panacea Venture

20.90%

BioFortune Inc

9.51%

Wei (Zheng)

7.97%

Qiming Venture Partners

7.69%

Shanghai Minhui Enterprise Management Consulting Partnership

7.61%

Other

46.33%

Popular Instruments

FAQs

What is the current price of Connect Biopharma Holdings Ltd (CNTB)?



The current price of Connect Biopharma Holdings Ltd (CNTB) is 2.21.

What is the symbol of Connect Biopharma Holdings Ltd?



The ticker symbol of Connect Biopharma Holdings Ltd is CNTB.

What is the 52-week high of Connect Biopharma Holdings Ltd?



The 52-week high of Connect Biopharma Holdings Ltd is 3.82.

What is the 52-week low of Connect Biopharma Holdings Ltd?



The 52-week low of Connect Biopharma Holdings Ltd is 0.73.

What is the market capitalization of Connect Biopharma Holdings Ltd?



The market capitalization of Connect Biopharma Holdings Ltd is 138.28M.

Is Connect Biopharma Holdings Ltd (CNTB) currently rated as Buy, Hold, or Sell?



According to analysts, Connect Biopharma Holdings Ltd (CNTB) has an overall rating of Buy, with a price target of 7.12.

What is the Earnings Per Share (EPS TTM) of Connect Biopharma Holdings Ltd (CNTB)?



The Earnings Per Share (EPS TTM) of Connect Biopharma Holdings Ltd (CNTB) is -1.00.